LIORESAL INTRATHECAL Rx
Generic Name and Formulations:
Baclofen 50mcg/mL, 500mcg/mL, 2000mcg/mL; for intrathecal inj; preservative-free.
Indications for LIORESAL INTRATHECAL:
Severe spasticity of cerebral or spinal origin, when oral baclofen is not appropriate.
Adults and Children:
<4yrs: not established. ≥4yrs: Give test dose 1st by intrathecal inj via spinal catheter or lumbar puncture (see full labeling for dose and timing; use 50mcg/mL syringe). Dose titration: see full labeling. Maintenance: titrate individually; use lowest effective dose; maintain muscle tone possibly close to normal. Spinal cord origin: usually 300–800mcg/day. Cerebral origin: usually 90–703mcg/day. Avoid abrupt cessation (may be severe/fatal); closely monitor pump, alarms, and refill schedule; wean orally-administered antispasticity drugs carefully.
Not for IV, IM, SC or epidural administration.
Do not discontinue abruptly; may result in high fever, altered mental status, rebound spasticity, muscle rigidity. Have resuscitative equipment and trained personnel available. Apparent risk patients (eg, spinal cord injury at T-6 or higher, communicative impairment, history of withdrawal symptoms): closely monitor infusion system, dosing schedule, refills, pump alarms, clinical signs of withdrawal or overdose. Do not use chronically if test dose ineffective. For chronic dosing use approved pump (eg, Medtronic SynchroMed Infusion System). Allow at least one year after traumatic brain injury before starting. Infections. Psychosis. Schizoaffective disorders. Confusion. Autonomic dysreflexia. Renal impairment. Hospitalize immediately if pump malfunction suspected. Pregnancy (Cat.C). Nursing mothers: not recommended.
Hypotension, dyspnea with morphine. Additive CNS depression with alcohol, other CNS depressants. Do not mix with other drugs in pump or catheter.
Muscle relaxant (central), antispastic agent.
Hypotonia, somnolence, dizziness, nausea, vomiting, paresthesia, headache, convulsion, hypotension, agitation, constipation, leukocytosis, chills, urinary retention, coma, drowsiness, psychosis, confusion; CNS depression, cardiovascular collapse, respiratory failure; others.
Single use ampules—1; Refill Kits—1, 2 (w. ampules and supplies)
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|